Argireline dosage and evidence

What is Argireline?

How does Argireline work?

It copies part of a protein called SNAP-25. That slightly blocks the nerve signal that makes facial muscles squeeze, softening expression lines.

What have studies in people found about Argireline?

Argireline has been tested in six small studies in people. The biggest had 60 people for four weeks. The wrinkle studies with good results came from the team that invented it, from cosmetic companies that sell it, or gave no word on who paid. The studies with no company behind them, one on faces and two on an eyelid spasm disorder, found no clear effect.

• Wrinkles around the eyes, China, 2013, 60 people: for every three on the cream, one got a dummy cream, used twice a day for four weeks. On an overall look, 48.9 percent of the cream group had fewer wrinkles, against none on the dummy. Skin moulds read by a machine showed smoother skin in the cream group and no change on the dummy. The record says nothing about who paid or about conflicts of interest.
• A serum with five active ingredients, 2026, two studies: 50 people with still wrinkles and 42 with wrinkles that show when the face moves. The serum held Argireline plus four other actives. After 12 weeks, still-wrinkle scores improved 35 to 69 percent and moving-wrinkle scores 10 to 13 percent. Every author works at a L'Oreal research centre. With four other actives in the bottle, none of this can be credited to Argireline alone.
• Eyelid spasm, paid for by the US government, 2013, 24 people: all were already getting botulinum toxin (Botox) shots every three months. Each added a daily Argireline cream or a dummy cream, and nobody knew which. Relief lasted 3.7 months on the peptide against 3.0 on the dummy. The authors call that a lean, not a clear difference. Four of the 12 on the cream had relief that lasted 3.3 to 7.1 months. There were no serious side effects. A second government study of the same question was stopped with 8 people enrolled.
• Crow's feet, Indonesia, 2023, 21 women aged 26 to 55: about seven each got an Argireline cream, a different peptide cream (palmitoyl pentapeptide-4) or a dummy cream, twice a day for eight weeks. Nobody knew who got which. Skin was checked with instruments, photos and a wrinkle scale. The other peptide did better than both Argireline and the dummy. The authors call it early work that needs more people. They reported no conflicts.
• Split-face test, 2023, 19 women: the same hyaluronic acid serum went on both sides of the face twice a day for four weeks, with Argireline added on one side only. Nobody knew which side. A skin camera read the wrinkles. Scores dropped a little on both sides, not enough to count on either, and the two sides ended up the same. The author declares no competing interests and says the companies involved had no say.
• The first report, 2002: a cream with 10 percent Argireline cut wrinkle depth by up to 30 percent after 30 days in healthy women. It does not say how many women. It came from the team that designed and named the peptide, and the record has no statement on funding or conflicts.
• Safety panel, 2025: the US expert panel on cosmetic ingredients judged it safe in cosmetics as used now, up to 0.005 percent. Above that strength, it says there is not enough data to call it safe.

What this does not tell you: The biggest study was 60 people for four weeks. The longest was 12 weeks, and that one tested a five-ingredient serum. No study in people has measured muscle or nerve activity in facial skin, so the claimed way it works, by blocking the nerve signal that tightens face muscles, has never been seen in a person. A 2025 review states the delivery problem plainly. The peptide is water-loving and fairly large, it barely gets through the greasy outer layer of skin, and nobody knows if it reaches the nerve endings at all. The two studies that tested the muscle claim head-on, in eyelid spasm, found no clear effect, and one was stopped. And the 10 percent cream in the first report is 2,000 times the 0.005 percent level where the safety panel had enough data. Above that level, the panel says it does not know.

The state of the research

The evidence, in charts

The studies we cite

• Study in people2002
  A synthetic hexapeptide (Argireline) with antiwrinkle activity

  The paper that launched the ingredient, written by the people who made it. It explains how the peptide is meant to work, by getting in the way of the machinery a muscle uses to contract. It also reports that a cream containing it reduced the depth of wrinkles. That test was small, and it sits in the same paper that introduces the molecule. Treat a first report from its own inventors as a starting point, not a verdict.

  Original report: Ac-EEMQRR-NH2 mimics SNAP-25 to interfere with SNARE assembly; topical use reduced wrinkle depth in a small study.

  PMID 18498523 International Journal of Cosmetic Science
• Study in people2013
  The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study

  In a short trial the cream beat a dummy cream, mostly on what people said about their own faces. Sixty people used one or the other for four weeks. Just under half the treated group counted as responding, against none of the dummy group. Measured skin roughness moved the same way. A gap that wide is unusual in cosmetic trials. Four weeks and sixty people is small, brief, and judged in part by opinion.

  60 subjects, 4 weeks: 48.9% subjective anti-wrinkle response versus 0% with placebo; roughness parameters decreased.

  PMID 23417317 American Journal of Clinical Dermatology
• Study in people2013
  Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy.

  This is the one test of the peptide in a medical condition, and it came up short. 24 people with uncontrollable eyelid spasms, already getting botulinum toxin every three months, had either acetyl hexapeptide-8 cream or a dummy cream added. Nobody involved knew which. Relief lasted about 3.7 months with the peptide and 3.0 without, too small a lean to count. Four of twelve on the active cream did hold out longer. No serious side effects appeared. Public money paid for this, not an ingredient maker.

  Double-blind placebo-controlled randomized trial in 24 patients with blepharospasm on regular three-monthly botulinum toxin. Time to return to baseline Jankovic score was 3.7 months on topical acetyl hexapeptide-8 against 3.0 on placebo, reported as a trend rather than a significant result; 4 of 12 in the active group had symptom control extended to 3.3 to 7.1 months. No significant adverse events. Sponsored by the National Institute of Neurological Disorders and Stroke, not by an ingredient manufacturer.

  PMID 23146065 European Journal of Neurology
• Study in people2015
  Placebo Controlled Double Blind Study of Acetyl Hexapeptide-8 in Treatment of Blepharospasm

  The follow-up trial was stopped early and never reported a result. This was the government-funded second round of the same eyelid-spasm question. The registry shows it finished in May 2015 with 8 people actually enrolled, and lists it as terminated. Nothing has been posted. That is why this line of work is described here as unfinished rather than as failed. Nothing in this record tells you whether the cream works or does not.

  The NINDS follow-on phase 2 trial of topical acetyl hexapeptide-8 in blepharospasm. Listed as terminated with 8 participants actually enrolled, completed May 2015. The registry record is the reason this line of work is described here as unfinished rather than as negative.

  NCT01750346 ClinicalTrials.gov, National Institute of Neurological Disorders and Stroke
• Study in people2023
  Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia(®) Complexion Analysis camera system for objective skin analysis.

  This one had no seller behind it, and it found nothing. 19 women put the same hyaluronic acid serum on both sides of the face for four weeks, with Argireline added on one side only. Nobody involved knew which side was which, and a camera system read the wrinkles. Scores drifted down slightly on both sides, not enough to count on either, and the two sides ended up the same. The author declares no competing interests, and states the companies involved had no say in the study.

  Split-face double-blind study in 19 women: the same hyaluronic acid serum with and without Argireline on opposite sides of the face for four weeks, read by VISIA imaging. Wrinkle scores fell non-significantly on both sides (right p=0.060, left p=0.176) and the two sides did not differ (p=0.829). The author declares no competing interests and states the companies involved had no influence on the study, its analysis or its publication.

  PMID 38024099 GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW
• Study in people2023
  Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet.

  A small three-way test in which this peptide came last. 21 Indonesian women aged 26 to 55 were sorted by chance into three creams: acetylhexapeptide-3, palmitoyl pentapeptide-4, or a dummy. That is about seven women per group. Over eight weeks, instruments and a wrinkle scale put palmitoyl pentapeptide-4 ahead of both acetylhexapeptide-3 and the dummy. The authors call the work initial and say it needs a proper sample size. Seven people per group is too few to measure an effect from. No conflicts were reported.

  21 Indonesian women aged 26 to 55 randomized to acetylhexapeptide-3 cream, palmitoyl pentapeptide-4 cream or placebo for eight weeks, roughly seven per arm, assessed by Corneometer, Tewameter, Cutometer and a crow's feet grading scale. The authors report palmitoyl pentapeptide-4 performing better than acetylhexapeptide-3 and placebo, and describe the work as initial, needing an adequate sample size. No conflicts reported.

  PMID 36909866 Journal of Clinical and Aesthetic Dermatology
• Study in people2026
  The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies.

  Wrinkles improved, and every author works for L'Oreal. Two studies were run, 50 people for still wrinkles and 42 for the wrinkles that appear when the face moves. After twelve weeks the still-wrinkle scores improved a lot and the moving-wrinkle scores improved a little. Nothing here can be credited to acetyl hexapeptide-8 on its own. Four other active ingredients sat in the same serum and changed at the same time. The authors are employed at L'Oreal research centres in China, the United States and Japan.

  Two clinical studies, 50 subjects for static wrinkles and 42 for dynamic wrinkles, of a serum containing acetyl hexapeptide-8 with four other actives. Static wrinkle scores improved 35 to 69 percent at 12 weeks and dynamic wrinkle scores 10 to 13 percent (all p<0.001). Every author is employed at a L'Oreal research and innovation centre in China, the United States or Japan, and the peptide is one of five actives, so no part of the result is attributable to it alone.

  PMID 41668671 International Journal of Cosmetic Science
• Review of studies2025
  Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy.

  A review that names the problem the marketing skips: the peptide struggles to get into the skin. It is water-loving and fairly large, and the outer layer of skin is greasy and built to keep such things out. Whether any of it reaches the nerve endings it is supposed to act on is still unknown. The authors conclude that poor penetration limits how much gets in, and that the reason for the reported cosmetic effects is not understood. They declare no conflicts.

  States the delivery problem plainly: the peptide is hydrophilic and relatively large, permeability through the lipophilic stratum corneum is limited, emulsion strategies have been built to improve it, and whether it reaches neuromuscular junctions after topical application remains uncertain. Concludes that low penetration limits bioavailability and that the mechanism behind the reported cosmetic effects is incompletely understood. The authors declare no conflicts of interest.

  PMID 40565185 International Journal of Molecular Sciences
• Review of studies2025
  Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics.

  A safety panel, not an efficacy study, and the concentration limit is the interesting part. The Expert Panel for Cosmetic Ingredient Safety judged acetyl hexapeptide-8 amide safe in cosmetics as currently used, up to five thousandths of one percent. Above that, it said the data are not enough to call it safe. The study that made this ingredient's name used a preparation two thousand times stronger than that ceiling. Nobody was treated here; the panel read existing data.

  The Expert Panel for Cosmetic Ingredient Safety concluded that acetyl hexapeptide-8 amide is safe in cosmetics at present practices of use up to 0.005 percent, and that the available data are insufficient to determine that it is safe above that concentration. The originating efficacy study used a 10 percent emulsion.

  PMID 40673537 International Journal of Toxicology